J&J Covid Vaccine Reviewed by EU Regulator After Blood Clots
- Safety review follows concerns involving AstraZeneca shot
- Four cases of clots, one fatality identified by regulator
This article is for subscribers only.
The European Union’s drug regulator has started a review to assess blood clots in people who received Johnson & Johnson’s Covid-19 vaccine.
Four serious cases of unusual clots accompanied by low blood platelets, one of which was fatal, have emerged after immunization with the J&J shot, the European Medicines Agency said Friday. The regulator is now scrutinizing potential safety issues for two Covid vaccines, after AstraZeneca Plc’s shot was possibly linked to a rare blood-clotting disorder.